Explore Chlamydia trachomatis serovar L2, NusB function in bacterial transcription and recombinant NusB applications in molecular research.
Recombinant Chlamydia trachomatis serovar L2 N utilization substance protein B homolog (nusB)
Chlamydia trachomatis NusB is a bacterial transcription-associated protein predicted to participate in the regulation of transcription termination and antitermination. NusB homologues in model bacteria bind specific RNA elements and help assemble complexes that allow RNA polymerase to continue transcription through termination signals.
The availability of a recombinant Chlamydia trachomatis serovar L2 NusB protein gives researchers a laboratory reagent for investigating NusB structure, RNA binding, protein interactions, antibody recognition and bacterial transcriptional regulation.
Although the molecular mechanism of NusB has been extensively characterized in organisms such as Escherichia coli, its precise interactions and regulatory importance in C. trachomatis require further direct experimental validation.
What is Chlamydia trachomatis?
Chlamydia trachomatis is an obligate intracellular bacterium that can replicate only inside susceptible host cells. It is neither a virus nor a protozoan parasite. However, it is sometimes described as an intracellular parasite because it depends heavily on host-cell resources for replication.
Image Reference : Chlamydia trachomatis - Wikipedia
The organism has a biphasic developmental cycle consisting of infectious elementary bodies and metabolically active reticulate bodies. Elementary bodies enter host cells and differentiate into reticulate bodies, which replicate within an intracellular membrane-bound compartment called an inclusion. Reticulate bodies later reorganize into elementary bodies that can infect additional cells.
The bacterium has a compact genome and a limited metabolic repertoire compared with many free-living bacteria. Genome analysis of the L2/434/Bu strain identified a chromosome of approximately 1.04 Mb together with a small plasmid, illustrating the reduced genomic architecture associated with its intracellular lifestyle.
What type of bacteria is Chlamydia trachomatis?
Chlamydia trachomatis is a human-adapted, non-motile, obligate intracellular bacterial pathogen belonging to the family Chlamydiaceae.
Different groups of C. trachomatis serovars are associated with distinct biological and clinical patterns:
- Serovars A-C are primarily associated with ocular trachoma.
- Serovars D-K are primarily associated with urogenital infections.
- Serovars L1-L3 are associated with lymphogranuloma venereum, or LGV.
Image Reference : Serological types of C. trachomatis - ResearchGate
The recombinant NusB product discussed here originates from serovar L2, one of the invasive LGV-associated serovars. CDC guidance identifies L1, L2 and L3 as the serovars responsible for LGV.
Why is serovar L2 important in Chlamydia research?
Serovar L2 strains are widely used as experimental models because they can infect cultured cells efficiently and have been extensively studied at genomic, transcriptomic and cell-biological levels.
Compared with the more localized infections generally associated with urogenital serovars D–K, LGV-associated serovars can invade deeper tissues and involve the lymphatic system. Clinical LGV may present with proctocolitis, genital lesions or enlarged regional lymph nodes. These clinical features provide biological context for studying the distinct molecular characteristics of serovar L2. Reference
However, a purified recombinant NusB protein is a research reagent. It is not an infectious organism and is not intended to reproduce the complete developmental cycle or pathogenicity of serovar L2.
What is NusB?
NusB stands for N-utilization substance protein B. It belongs to a group of bacterial Nus factors involved in the regulation of transcription elongation, termination and antitermination.
NCBI’s Conserved Domain Database classifies NusB homologues within the transcription termination factor NusB family and identifies a conserved NusB RNA-binding domain. A C. trachomatis NusB sequence is represented within this conserved protein family. NCBI
In well-characterized bacterial systems, NusB works with other transcription-associated factors, particularly NusE, also known as ribosomal protein S10. Together, NusB and NusE recognize an RNA sequence called BoxA.
Formation of a NusB-NusE-BoxA complex helps initiate assembly of a larger antitermination complex. This complex modifies the behaviour of RNA polymerase and allows it to continue transcribing regions that might otherwise be affected by transcriptional pausing or termination. Structural studies show that specific RNA-protein and protein-protein contacts are required for this activity.
Image Reference : Nature
What is bacterial transcription antitermination?
Transcription normally ends when RNA polymerase encounters an effective termination signal. Antitermination describes a regulatory process through which RNA polymerase becomes resistant to selected termination signals and continues producing a longer RNA transcript.
In many bacteria, this mechanism is particularly important for ribosomal RNA transcription. Ribosomal RNA operons are long and must be transcribed efficiently to support ribosome production.
The bacterial antitermination machinery can include :
- NusA
- NusB
- NusE or ribosomal protein S10
- NusG
- SuhB
- BoxA-containing RNA
- RNA polymerase
NusB and NusE form an early RNA-recognition complex by binding BoxA. Additional factors subsequently assemble around the transcription elongation complex. Studies in model bacteria demonstrate that NusB contributes to efficient rRNA transcription, RNA recognition and correct ribosomal RNA maturation.
What is known about NusB expression in Chlamydia trachomatis?
Transcriptomic evidence indicates that C. trachomatis activates a large proportion of its compact genome soon after entering a host cell.
In a study examining the first hour of serovar L2 infection, nusB was among the genes showing significant early transcriptional activation. This observation is consistent with a requirement for rapid establishment of the bacterial transcription and translation machinery during the transition from an extracellular elementary body to an intracellular developmental state.
Comparative transcriptomic research has also reported altered expression of transcription elongation factors, including nusA, nusB and nusG, during chlamydial stress responses. This suggests that transcription-associated proteins may participate in adaptation to nutrient limitation, temperature changes, host immune pressure or other conditions that disrupt normal bacterial development.
These expression data support the relevance of NusB as a molecular research target. They do not, by themselves, prove that the C. trachomatis protein performs every function described for NusB in E. coli. Direct RNA-binding, structural and interaction studies remain necessary.
Why study recombinant Chlamydia trachomatis NusB?
Recombinant proteins allow individual bacterial components to be examined outside the complexity of the intact organism.
The recombinant Chlamydia trachomatis serovar L2 N-utilization substance protein B homolog is offered by Gentaur for laboratory and research use under catalogue reference 0544-MBS1194353-01. The listing includes multiple quantities and expression-system options, including bacterial, yeast, baculovirus and mammalian-cell formats. Researchers should confirm the exact sequence, tag, purity, buffer, concentration, storage conditions and lot-specific quality documentation before designing an experiment.
RNA-binding research :
Purified NusB can be evaluated for interaction with predicted BoxA-like or other RNA sequences using:
- Electrophoretic mobility-shift assays
- Fluorescence-polarization assays
- Surface plasmon resonance
- Microscale thermophoresis
- Isothermal titration calorimetry
- RNA pull-down experiments
- UV-crosslinking assays
These studies can determine whether the chlamydial protein binds RNA directly, identify preferred RNA motifs and calculate binding affinity.
Protein-interaction studies
Researchers can investigate whether C. trachomatis NusB interacts with NusE, NusA, NusG or other transcription-associated proteins.
Possible methods include affinity pull-down, co-immunoprecipitation, biolayer interferometry, yeast two-hybrid analysis, analytical size-exclusion chromatography and crosslinking mass spectrometry.
Because protein interactions may depend on the folding and modification state of the recombinant reagent, the selected expression system should be documented carefully.
Antibody production and validation :
Recombinant NusB may be considered as an immunogen or analytical standard during the development of research antibodies.
Potential applications include:
- Immunoblot validation
- ELISA development
- Antibody-affinity testing
- Competitive-binding assays
- Immunoprecipitation controls
- Quantitative protein standards
Researchers must first confirm that the supplied construct contains the epitopes required for the intended assay.
Structural biology :
The protein may support preliminary crystallization, nuclear magnetic resonance or cryo-electron microscopy workflows.
Structural comparison with NusB homologues from other bacteria could reveal conserved RNA-binding surfaces and lineage-specific features associated with the reduced chlamydial genome.
Screening for NusB-binding molecules :
Recombinant NusB can also be used in exploratory binding screens designed to identify compounds or molecular fragments that interact with the protein.
A detected interaction should not automatically be interpreted as antimicrobial activity. Follow-up experiments must demonstrate target engagement, functional inhibition, selectivity and activity in an appropriate intracellular infection model.
Recommended experimental workflow
A robust NusB study should begin with verification of protein identity and quality. Researchers can then assess structural integrity before moving to functional assays.
A practical workflow may involve:
1- Confirming molecular mass and purity by SDS-PAGE and mass spectrometry.
2- Evaluating aggregation by size-exclusion chromatography or dynamic light scattering.
3- Testing folding using circular dichroism or thermal-shift analysis.
4- Measuring binding to candidate RNA sequences.
5- Testing interaction with recombinant NusE or other Nus factors.
6- Mutating predicted RNA-binding residues.
7- Comparing wild-type and mutant proteins.
8- Validating findings inside C. trachomatis-infected cells.
9- Examining the effect of nusB suppression or modification on bacterial transcription and development.
In-vitro protein-binding data should be integrated with cellular transcriptomics, microscopy and genetic evidence before conclusions are made about the role of NusB during infection.
Conclusion
Chlamydia trachomatis NusB is a conserved bacterial transcription-associated protein with a predicted role in RNA recognition and transcription antitermination.
Evidence from model bacteria demonstrates that NusB can cooperate with NusE to recognize BoxA RNA and initiate assembly of an antitermination complex. Transcriptomic studies further show that nusB is actively expressed during early C. trachomatis infection and can respond to bacterial stress conditions.
The recombinant Chlamydia trachomatis serovar L2 NusB protein available from Gentaur may support RNA-binding analysis, protein-interaction studies, antibody development, structural biology and exploratory molecular screening.
However, functions inferred from other bacterial species should be validated directly in the chlamydial system. Researchers should also verify all construct- and lot-specific characteristics before selecting the reagent for a particular application.
Frequently asked questions
What is Chlamydia trachomatis?
=> Chlamydia trachomatis is an obligate intracellular bacterium that infects human epithelial cells. Different serovars are associated with ocular disease, urogenital infection or lymphogranuloma venereum.
What type of bacteria is Chlamydia trachomatis?
=> It is a non-motile, obligate intracellular bacterial pathogen belonging to the family Chlamydiaceae.
Is Chlamydia trachomatis a parasite?
=> It is scientifically classified as a bacterium. It may be called an obligate intracellular parasite because it depends on living host cells, but it is not a protozoan parasite.
What diseases can Chlamydia trachomatis cause?
=> Depending on the serovar, it can cause trachoma, urogenital chlamydia and lymphogranuloma venereum. Untreated genital infection can contribute to pelvic inflammatory disease, infertility and ectopic pregnancy.
What is Chlamydia trachomatis serovar L2?
=> Serovar L2 belongs to the LGV group of invasive C. trachomatis serovars. It is also commonly used in laboratory research on chlamydial infection and intracellular development.
What is NusB?
=> NusB is an RNA-binding bacterial transcription factor associated with transcription antitermination and regulation of ribosomal RNA synthesis.
Does recombinant NusB contain live Chlamydia trachomatis?
=> No. A recombinant NusB preparation contains an experimentally produced protein rather than viable C. trachomatis organisms.
Can recombinant NusB diagnose chlamydia?
=> No. The recombinant protein is intended for laboratory research and is not a clinical diagnostic test.
Can recombinant NusB treat Chlamydia infection?
=> No. It is not an antibiotic, vaccine or therapeutic product.
Where can researchers obtain recombinant Chlamydia trachomatis NusB?
=> Researchers can review the available formats on the Gentaur recombinant Chlamydia trachomatis serovar L2 NusB product page.
For research use only. Not intended for diagnostic or therapeutic use.